A focused 2026 clinical landscape deep dive into NCT07702032, evaluating Petosemtamab in RAS/BRAF Wild Type Colorectal Cancer: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.

Bicara Therapeutics 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

A focused 2026 clinical landscape deep dive into NCT07702656, evaluating SYS6026 in Cervical Intraepithelial Neoplasia: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.

Lyell Immunopharma 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

A focused 2026 clinical landscape deep dive into JPRN-jRCT2031260310, evaluating Alixorexton in Narcolepsy: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.

Fate Therapeutics 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Nkarta 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

A focused 2026 clinical landscape deep dive into JPRN-jRCT2031260309, evaluating Alixorexton in Narcolepsy: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.

Autolus Therapeutics 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

A focused 2026 clinical landscape deep dive into JPRN-jRCT2031260308, evaluating Alixorexton in Narcolepsy: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.

Arcellx 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

A focused 2026 clinical landscape report on CTR20262629, evaluating TQA Gel Patch in Osteoarthritis, Knee, covering trial design, endpoints, sponsor context, readout timing and development white space.